Key facts
- This page summarizes Gabriel S. Morris's Form 4 filing for Immix Biopharma, Inc. (IMMX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 29 May 2026, 17:05.
Gabriel S. Morris - 22 May 2026 Form 4 Insider Report for Immix Biopharma, Inc. (IMMX)
- Reporting relationship
- CFO, President, Director
- Issuer ticker
- IMMX
- Reported as of
- 22 May 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 29 May 2026, 17:05:22 UTC
- Prior SEC filing
- 10 Dec 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Gabriel S. Morris
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Gabriel S. Morris filed Form 4 for Immix Biopharma, Inc. (IMMX) on 29 May 2026.
Change
- Previous filing in this sequence was filed on 10 Dec 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001889967
Primary reporting owner
Morris Gabriel S
- Relationship
- CFO, President, Director
- Address
- C/O IMMIX BIOPHARMA, INC., 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES
- Signature
- /s/ Gabriel S. Morris
- Signature date
- 29 May 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IMMX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +500,000
- Change %
- Price
- $0.000000*
- Shares after
- 500,000
- Date
- 22 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 500,000
- Exercise price
- $8.78
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The Stock Option will vest in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer.